Novo’s $1.4 Billion Bet on the Future of Oral Drugs
Novo Nordisk is backing Orbis Medicines in a deal worth up to $1.4 billion, betting that AI-enabled drug discovery can help turn traditionally injectable treatments into oral medicines.
Scientific Publishing
1 story tagged Scientific Publishing.
More Topics
- Action Direction
- AI Startups
- AI Transformation
- Amazon
- Anthropic
- Apple
- Art & Design
- Artificial Intelligence
- Automation
- Aviation
- Blown Glass
- Bond Markets
- Brand Identity
- Brand Management
- Brand Strategy
- Brandunder
- Canton Fair
- China
- Claude
- Cloud Computing
- Collectible Design
- Competition Policy
- Consulting
- Consumer Behaviour
- Consumer Price Index
- Consumer Technology
- Corporate Governance
- Cost Of Capital
- Cybersecurity
- Data Centres
- Design
- Digital Branding
- Digital Transformation
- Direct-to-Consumer
- E-commerce
- Energy
- Engineering
- Enterprise Software
- Europe
- Export
- Fashion
- Fed
- Federal Reserve
- Film Production
- Finance
- Financial Reporting
- Founder-Led Brands
- Future Of Work
- Global Economy
- Global Fair
- Global Marketing Summit
- Growth
- Guangzhou
- Independent Artists
- Industrial Strategy
- Inflation
- Innovation
- Interest Rates
- inve
- Investment
- Istanbul
- ITGT Consultancy
- Izmir
- Labour Markets
- Leadership
- Licensing
- Live Events
- Luxury
- LVMH
- Market
- Marketing
- Materials Science
- Mergers And Acquisitions
- Mobile Apps
- Neuromarketing
- Neuroscience
- New York
- Nuclear Power
- Oil
- OpenAI
- Partner
- Premier League
- Pricing
- Product Strategy
- Productivity
- Qualcomm
- Real Estate Investment
- Retail
- Robotics
- Semiconductors
- Special Effects
- Sponsorship
- Sports Business
- Sports Media
- Startup Ecosystem
- Startup Funding
- Startups
- Streaming
- Talent And Agencies
- Technological Change
- Technology Policy
- Television
- Tesla
- Turkish Airlines
- Turkiye
- U.S. Treasury Market
- Unicorns
- Venture Capital
- Womenswear